Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brelovitug - Bluejay Therapeutics

Next Previous
Drug Profile

Brelovitug - Bluejay Therapeutics

Alternative Names: BJT-778

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Bluejay Therapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis B surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis D
  • Phase II Hepatitis B

Most Recent Events

  • 28 Aug 2025 Phase-III clinical trials in Hepatitis D (Monotherapy) in United Kingdom, Switzerland, Spain, Romania, Italy, France, Czech Republic, Germany, Sweden (SC) (CTIS2024-517167-23-00)
  • 28 Aug 2025 Phase-III clinical trials in Hepatitis D (Monotherapy) in Austria (SC) (CTIS2024-517167-23-00)
  • 25 Mar 2025 Phase-II/III clinical trials in Hepatitis D (Monotherapy) in Ukraine, Georgia, Bulgaria, Israel, USA (SC) (NCT06907290)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top